Staff Profile

I am a State Registered Clinical Cytogeneticist and I worked for 7 years in the National Health Service. I now have over 10 years research experience. Since moving into research in 2008, I have led a range of projects in the field of genetics of acute leukaemia in children. I have been responsible for the introduction and integration of novel molecular tests (fluorescence in situ hybridisation (FISH), multiplex ligation-dependent probe amplification (MLPA) and genome-wide SNP array) into routine practice within the UK acute leukaemia treatment trials.

Qualifications

• PhD by published works - Identification and Characterisation of Cytogenetic Subgroups in Childhood B-cell Precursor Acute Lymphoblastic Leukaemia  Newcastle University (2018)
• Registered Clinical Scientist with the Health Professions Council (HPC)(Since Feb 2005)
• BSc (Hons) Genetics Newcastle University (2000)   

Prizes

• Newcastle University Medical Sciences Doctoral Prize for Outstanding Thesis (2019) 

Funding

• Co-applicant on Blood Cancer UK Continuity Grant (2021-23) - “Refined risk stratification for children with acute myeloid leukaemia treated on Myechild 01 and acute lymphoblastic leukaemia on UKALL2011”

Google scholar: Click here

In contrast to childhood acute lymphoblastic leukaemia (ALL) with >90% survival rates, acute myeloid leukaemia (AML) in children has a high relapse rate (30-40%) and although a rare disease remains a major cause of childhood cancer mortality. In previous UK AML treatment trials, children were classified and treated alongside adult patients. Recently, an international treatment trial specifically for childhood AML, MyeChild 01 has recruited more than 700 patients (0-18 years) from centres in the UK, Republic of Ireland, France, Australia and New Zealand. Risk stratification for treatment was based on diagnostic cytogenetics and limited molecular markers. In ~70% of childhood AML, a fusion gene, NPM1 mutation or FLT3-ITD was detected. The remaining 30% had no prognostic marker.

As part of my role within the Leukaemia Research Cytogenetics Group (LRCG), I am the genetics co-ordinator for the Myechild 01 trial. This role involves curation and integration of all standard-of-care genetic data generated within the regional NHS genetic laboratories to ensure accuracy of results. I designed the testing algorithm for the rare (often cryptic) risk stratifying abnormalities, developing and refining specialist genetic tests throughout the trial. This algorithm was adopted in UK and Australasia.

During the trial, I also oversaw the collection of diagnostic bone marrow samples from the individual treatment centres, with approval from MyeChild 01, for transcriptome (RNAseq) and whole genome sequencing (WGS). The resulting cohort consists of >600 samples with high quality DNA and RNA, linked to excellent genetic and clinical annotation. My current research is focused on maximising the output from this precious dataset.

Student Supervision

MRes: Project Supervisor for ten MRes students (2012-2022)

BSc: Project Supervisor for ten undergraduate students (Biomedical Sciences) (2012-2022)

Lecturing

BGM 3060 - Diagnostic Medical Genetics (2016-present)

• Articles

  • Ryan SL, Peden JF, Kingsbury Z, Schwab CJ, James T, Polonen P, Mijuskovic M, Becq J, Yim R, Cranston RE, Hedges DJ, Roberts KG, Mullighan CG, Vora A, Russell LJ, Bain R, Moorman AV, Bentley DR, Harrison CJ, Ross MT. Whole genome sequencing provides comprehensive genetic testing in childhood B-cell acute lymphoblastic leukaemia. Leukemia 2023, 37, 518-528.
  • Schwab C, Cranston RE, Ryan SL, Butler E, Winterman E, Hawking Z, Bashton M, Enshaei A, Russell LJ, Kingsbury Z, Peden JF, Barretta E, Murray J, Gibson J, Hinchliffe AC, Bain R, Vora A, Bentley DR, Ross MT, Moorman AV, Harrison CJ. Integrative genomic analysis of childhood acute lymphoblastic leukaemia lacking a genetic biomarker in the UKALL2003 clinical trial. Leukemia 2023, 37, 529-538.
  • Masic D, Fee K, Bell H, Case M, Witherington G, Lansbury S, Ojeda-Garcia J, McDonald D, Schwab C, Van Delft FW, Filby A, Irving JAE. Hyperactive CREB subpopulations increase during therapy in pediatric B-lineage acute lymphoblastic leukemia. Haematologica 2023, 108(4), 981-992.
  • Moorman AV, Barretta E, Butler ER, Ward EJ, Twentyman K, Kirkwood AA, Enshaei A, Schwab C, Creasey T, Leongamornlert D, Papaemmanuil E, Patrick P, Clifton-Hadley L, Patel B, Menne T, McMillan AK, Harrison CJ, Rowntree CJ, Marks DI, Fielding AK. Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study. Leukemia 2022, 36, 625-636.
  • Pal D, Blair H, Parker J, Hockney S, Beckett M, Singh M, Tirtakusuma R, Nelson R, McNeill H, Angel SH, Wilson A, Nizami S, Nakjang S, Zhou P, Schwab C, Sinclair P, Russell LJ, Coxhead J, Halsey C, Allan JM, Harrison CJ, Moorman AV, Heidenreich O, Vormoor J. hiPSC-derived bone marrow milieu identifies a clinically actionable driver of niche-mediated treatment resistance in leukemia. Cell Reports Medicine 2022, 3(8), 100717.
  • Schwab CJ, Murdy D, Butler E, Enshaei A, Winterman E, Cranston RE, Ryan S, Barretta E, Hawking Z, Murray J, Antony G, Vora A, Moorman AV, Harrison CJ. Genetic characterisation of childhood B-other-acute lymphoblastic leukaemia in UK patients by fluorescence in situ hybridisation and Multiplex Ligation-dependent Probe Amplification. British Journal of Haematology 2022, 196(3), 753-763.
  • Creasey T, Enshaei A, Nebral K, Schwab C, Watts K, Cuthbert G, Vora A, Moppett J, Harrison CJ, Fielding AD, Haas OA, Moorman AV. Single nucleotide polymorphism (SNP) array-based signature of low hypodiploidy in acute lymphoblastic leukemia. Genes Chromosomes Cancer 2021, 60(9), 604-615.
  • Bardelli V, Arniani S, Pierini V, Pierini T, Di Giacomo D, Gorello P, Moretti M, Pellanera F, Elia L, Vitale A, Storlazzi CT, Tolomeo D, Mastrodicasa E, Caniglia M, Chiaretti S, Ruggeri L, Roti G, Schwab C, Harrison CJ, Almeida A, Pieters T, Van Vlierberghe P, Mecucci C, La Starza R. MYB rearrangements and over-expression in T-cell acute lymphoblastic leukemia. Genes Chromosomes and Cancer 2021, 60(7), 482-488.
  • Boer JM, Valsecchi MG, Hormann FM, Antic Z, Zaliova M, Schwab C, Cazzaniga G, Arfeuille C, Cave H, Attarbaschi A, Strehl S, Escherich G, Imamura T, Ohki K, Gruber TA, Sutton R, Pastorczak A, Lammens T, Lambert F, Li CK, Carrillo de Santa Pau E, Hoffmann S, Moricke A, Harrison CJ, Den Boer ML, De Lorenzo P, Stam RW, Bergmann AK, Pieters R. Favorable outcome of NUTM1-rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia in a collaborative international study. Leukemia 2021, 35, 2978-2982.
  • La Starza R, Pierini V, Pierini T, Nofrini V, Matteucci C, Arniani S, Moretti M, Lema Fernandez AG, Pellanera F, Di Giacomo D, Storlazzi TC, Vitale A, Gorello P, Sammarelli G, Roti G, Basso G, Chiaretti S, Foa R, Schwab C, Harrison CJ, Van Vlierberghe P, Mecucci C. Design of a Comprehensive Fluorescence in Situ Hybridization Assay for Genetic Classification of T-Cell Acute Lymphoblastic Leukemia. Journal of Molecular Diagnostics 2020, 22(5), 629-639.
  • Bashton M, Hollis R, Ryan S, Schwab CJ, Moppett J, Harrison CJ, Moorman AV, Enshaei A. Concordance of copy number abnormality detection using SNP arrays and Multiplex Ligation-dependent Probe Amplification (MLPA) in acute lymphoblastic leukaemia. Scientific Reports 2020, 10, 45.
  • Moorman AV, Schwab C, Winterman E, Hancock J, Castleton A, Cummins M, Gibson B, Goulden N, Kearns P, James B, Kirkwood AA, Lancaster D, Madi M, McMillan A, Motwani J, Norton A, O'Marcaigh A, Patrick K, Bhatnagar N, Qureshi A, Richardson D, Stokley S, Taylor G, van Delft FW, Moppett J, Harrison CJ, Samarasinghe S, Vora A. Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL-class fusion. British Journal of Haematology 2020, 191(5), 844-851.
  • Enshaei A, O'Connor D, Bartram J, Hancock J, Harrison CJ, Hough R, Samarasinghe S, den Boer ML, Boer JM, de Groot-Kruseman HA, Marquart HV, Noren-Nystrom U, Schmiegelow K, Schwab C, Horstmann MA, Escherich G, Heyman M, Pieters R, Vora A, Moppett J, Moorman AV. A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia. Blood 2020, 135(17), 1438-1446.
  • Hamadeh L, Enshaei A, Schwab C, Alonso CN, Attarbaschi A, Barbany G, den Boer ML, Boer JM, Braun M, Dalla Pozza L, Elitzur S, Emerenciano M, Fechina L, Felice MS, Fronkova E, Haltrich I, Heyman MM, Horibe K, Imamura T, Jeison M, Kovács G, Kuiper RP, Mlynarski W, Nebral K, Ivanov Öfverholm I, Pastorczak A, Pieters R, Piko H, Pombo-de-Oliveira MS, Rubio P, Strehl S, Stary J, Sutton R, Trka J, Tsaur G, Venn N, Vora A, Yano M, Harrison CJ, Moorman AV. Validation of the United Kingdom copy-number alteration classifier in 3239 children with B-cell precursor ALL. Blood Advances 2019, 3(2), 148-157.
  • Sinclair PB, Ryan S, Bashton M, Hollern S, Hanna R, Case M, Schwalbe EC, Schwab CJ, Cranston RE, Young BD, Irving JAE, Vora AJ, Moorman AV, Harrison CJ. SH2B3 inactivation through CN-LOH-12q is uniquely associated with B-cell precursor ALL with iAMP21 or other chromosome 21 gain. Leukemia 2019, 33, 1881-1894.
  • Girardi T, Vereecke S, Sulima SO, Khan Y, Fancello L, Briggs JW, Schwab C, De Beeck JO, Verbeeck J, Royaert J, Geerdens E, Vicente C, Bornschein S, Harrison CJ, Meijerink JP, Cools J, Dinman JD, Kampen KR, De Keersmaecker K. The T-cell leukemia-associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling. Leukemia 2018, 32(3), 809-819.
  • Sinclair PB, Blair HH, Ryan SL, Buechler L, Cheng J, Clayton J, Hanna R, Hollern S, Hawking Z, Bashton M, Schwab CJ, Jones L, Russell LJ, Marr H, Carey P, Halsey C, Heidenreich O, Moorman AV, Harrison CJ. Dynamic clonal progression in xenografts of acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21. Haematologica 2018, 103, 634-644.
  • O'Connor D, Moorman AV, Wade R, Hancock J, Tan RMR, Bartram J, Moppett J, Schwab C, Patrick K, Harrison CJ, Hough R, Goulden N, Vora A, Samarasinghe S. Use of minimal residual disease assessment to redefine induction failure in pediatric acute lymphoblastic leukemia. Journal of Clinical Oncology 2017, 35(6), 660-667.
  • Schwab CJ, Nebral K, Chilton L, Leschi C, Waanders E, Boer JM, Zaliova M, Sutton R, Ofverholm II, Ohki K, Yamashita Y, Groeneveld-Krentz S, Fronkova E, Bakkus M, Tchinda J, Conceicao-Barbosa T, Fazio G, Mlynarski W, Pastorczak A, Cazzaniga G, Pombo-de-Oliveira MS, Trka J, Kirschner-Schwabe R, Imamura T, Barbany G, Stanulla M, Attarbaschi A, Panzer-Grumayer R, Kuiper RP, den-Boer ML, Cave H, Moorman AV, Harrison CJ, Strehl S. Intragenic amplification of PAX5: a novel subgroup in B-cell precursor acute lymphoblastic leukemia?. Blood Advances 2017, 1, 1473-1477.
  • Enshaei A, OConnor D, Bartram J, Hancock J, Harrison CJ, Hough R, Samarasinghe S, Schwab C, Vora A, Wade R, Moppett J, Moorman AV, Goulden N. Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia. Journal of Clinical Oncology 2017, 36(1), 34-43.
  • Benard-Slagter A, Zondervan I, de Groot K, Ghazavi F, Sarhadi V, Van Vlierberghe P, De Moerloose B, Schwab C, Vettenranta K, Harrison CJ, Knuutila S, Schouten J, Lammens T, Savola S. Digital Multiplex Ligation-Dependent Probe Amplification for Detection of Key Copy Number Alterations in T- and B-Cell Lymphoblastic Leukemia. Journal of Molecular Diagnostics 2017, 19(5), 659-672.
  • Vormoor B, Veal GJ, Griffin MJ, Boddy AV, Irving J, Minto L, Case M, Banerji U, Swales KE, Tall JR, Moore AS, Toguchi M, Acton G, Dyer K, Schwab C, Harrison CJ, Grainger JD, Lancaster D, Kearns P, Hargrave D, Vormoor J. A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia. Pediatric Blood & Cancer 2017, 64(6), e26351 1-4.
  • Ryan SL, Matheson E, Grossmann V, Sinclair P, Bashton M, Schwab C, Towers W, Partington M, Elliott A, Minto L, Richardson S, Rahman T, Keavney B, Skinner R, Bown N, Haferlach T, Vandenberghe P, Haferlach C, Santibanez-Koref M, Moorman AV, Kohlmann A, Irving JA, Harrison CJ. The role of the RAS pathway in iAMP21-ALL. Leukemia 2016, 30, 1824-1831.
  • Irving JAE, Enshaei A, Parker CA, Sutton R, Kuiper RP, Erhorn A, Minto L, Venn NC, Law T, Yu J, Schwab C, Davies R, Matheson E, Davies A, Sonneveld E, den Boer ML, Love SB, Harrison CJ, Hoogerbrugge PM, Revesz T, Saha V, Moorman AV. Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukaemia. Blood 2016, 128(7), 911-922.
  • La Starza R, Barba G, Demeyer S, Pierini V, Di Giacomo D, Gianfelici V, Schwab C, Matteucci C, Vicente C, Cools J, Messina M, Crescenzi B, Chiaretti S, Foà R, Basso G, Harrison CJ, Mecucci C. Deletions of the long arm of chromosome 5 define subgroups of T-cell acute lymphoblastic leukemia. Haematologica 2016, 101(8), 951-958.
  • Zaliova M, Moorman AV, Cazzaniga G, Stanulla M, Harvey RC, Roberts KG, Heatley SL, Loh ML, Konopleva M, Chen IM, Zimmermannova O, Schwab C, Smith O, Mozziconacci MJ, Chabannon C, Kim M, Falkenburg JHF, Norton A, Marshall K, Haas OA, Starkova J, Stuchly J, Hunger SP, White D, Mullighan CG, Willman CL, Stary J, Trka J, Zuna J. Characterization of leukemias with ETV6-ABL1 fusion. Haematologica 2016, 101(9), 1082-1093.
  • Schwab C, Ryan SL, Chilton L, Elliott A, Murray J, Richardson S, Wragg C, Moppett J, Cummins M, Tunstall O, Parker CA, Saha V, Goulden N, Vora A, Moorman AV, Harrison CJ. EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications. Blood 2016, 127(18), 2214-2218.
  • Goossens S, Radaelli E, Blanchet O, Durinck K, Van der Meulen J, Peirs S, Taghon T, Tremblay CS, Costa M, Ghahremani MF, De Medts J, Bartunkova S, Haigh K, Schwab C, Farla N, Pieters T, Matthijssens F, Van Roy N, Best JA, Deswarte K, Bogaert P, Carmichael C, Rickard A, Suryani S, Bracken LS, Alserihi R, Cante-Barret K, Haenebalcke L, Clappier E, Rondou P, Slowicka K, Huylebroeck D, Goldrath AW, Janzen V, McCormack MP, Lock RB, Curtis DJ, Harrison C, Berx G, Speleman F, Meijerink JPP, Soulier J, Van Vlierberghe P, Haigh JJ. ZEB2 drives immature T-cell lymphoblastic leukaemia development via enhanced tumour-initiating potential and IL-7 receptor signalling. Nature Communications 2015, 6, 5794.
  • Vicente C, Schwab C, Broux M, Geerdens E, Degryse S, Demeyer S, Lahortiga I, Elliott A, Chilton L, LaStarza R, Mecucci C, Vandenberghe P, Goulden N, Vora A, Moorman AV, Soulier J, Harrison CJ, Clappier E, Cools J. Targeted Sequencing Identifies Association Between IL7R-JAK Mutations And Epigenetic Modulators In T-Cell Acute Lymphoblastic Leukemia. Haematologica 2015, 100, 1301-1310.
  • Nicholson L, Evans C, Matheson E, Minto L, Keilty C, Sanichar M, Case M, Schwab C, Williamson D, Rainer J, Harrison C, Kofler R, Hall AG, Rednern CPF, Wheaton AD, Irving JAE. Quantitative proteomic analysis reveals maturation as a mechanism underlying glucocorticoid resistance in B lineage ALL and re-sensitization by JNK inhibition. British Journal of Haematology 2015, 171(4), 595–605.
  • Boer JM, vanderVeer A, Rizopoulos D, Fiocco M, Sonneveld E, deGroot-Kruseman HA, Kuiper RP, Hoogerbrugge P, Horstmann M, Zaliova M, Palmi C, Trka J, Fronkova E, Emerenciano M, Pombo-de-Oliveira MS, Mlynarski W, Szczepanski T, Nebral K, Attarbaschi A, Venn N, Sutton R, Schwab CJ, Enshaei A, Vora A, Stanulla M, Schrappe M, Cazzaniga G, Conter V, Zimmermann M, Moorman AV, Pieters R, denBoer ML. Prognostic value of rare IKZF1 deletion in childhood b-cell precursor acute lymphoblastic leukemia: an international collaborative study. Leukemia 2015, 1-7.
  • Gabriel AS, Lafta FM, Schwalbe EC, Nakjang S, Cockell SJ, Iliasova A, Enshaei A, Schwab C, Rand V, Clifford SC, Kinsey SE, Mitchell CD, Vora A, Harrison CJ, Moorman AV, Strathdee G. Epigenetic landscape correlates with genetic subtype but does not predict outcome in childhood acute lymphoblastic leukemia. Epigenetics 2015, 10(8), 717-726.
  • Patel B, Dey A, Castleton AZ, Schwab C, Samuel E, Sivakumaran J, Beaton B, Zareian N, Zhang CY, Rai L, Enver T, Moorman AV, Fielding AK. Mouse xenograft modeling of human adult acute lymphoblastic leukemia provides mechanistic insights into adult LIC biology. Blood 2014, 124(1), 96-105.
  • La Starza R, Borga C, Barba G, Pierini V, Schwab C, Matteucci C, Fernandez AGL, Leszl A, Cazzaniga G, Chiaretti S, Basso G, Harrison CJ, te Kronnie G, Mecucci C. Genetic profile of T-cell acute lymphoblastic leukemias with MYC translocations. Blood 2014, 124(24), 3577-3582.
  • Li Y, Schwab C, Ryan SL, Papaemmanuil E, Robinson HM, Jacobs P, Moorman AV, Dyer S, Borrow J, Griffiths M, Heerema NA, Carroll AJ, Talley P, Bown N, Telford N, Ross FM, Gaunt L, McNally RJ, Young BD, Sinclair P, Rand V, Teixeira MR, Joseph O, Robinson B, Maddison M, Dastugue N, Vandenberghe P, Haferlach C, Stephens PJ, Cheng J, Van-Loo P, Stratton MR, Campbell PJ, Harrison CJ. Constitutional and somatic rearrangement of chromosome 21 in acute lymphoblastic leukaemia. Nature 2014, 508(7494), 98-102.
  • Moorman AV, Enshaei A, Schwab C, Wade R, Chilton L, Elliott A, Richardson S, Hancock J, Kinsey SE, Mitchell CD, Goulden N, Vora A, Harrison CJ. A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia. Blood 2014, 124(9), 1434-1444.
  • Moorman AV, Robinson H, Schwab C, Richards SM, Hancock J, Mitchell CD, Goulden N, Vora A, Harrison CJ. Risk-Directed Treatment Intensification Significantly Reduces the Risk of Relapse Among Children and Adolescents With Acute Lymphoblastic Leukemia and Intrachromosomal Amplification of Chromosome 21: A Comparison of the MRC ALL97/99 and UKALL2003 Trials. Journal of Clinical Oncology 2013, 31(27), 3389-3396.
  • Enshaei A, Schwab CJ, Konn ZJ, Mitchell CD, Kinsey SE, Wade R, Vora A, Harrison CJ, Moorman AV. Long-term follow-up of ETV6-RUNX1 ALL reveals that NCI risk, rather than secondary genetic abnormalities, is the key risk factor. Leukemia 2013, 27(11), 2256-2259.
  • Schwab CJ, Chilton L, Morrison H, Jones L, Al-Shehhi H, Erhorn A, Russell LJ, Moorman AV, Harrison CJ. Genes commonly deleted in childhood B-cell precursor acute lymphoblastic leukemia: association with cytogenetics and clinical features. Haematologica 2013, 98(7), 1081-1088.
  • Harrison CJ, Moorman AV, Schwab C, Carroll AJ, Raetz EA, Devidas M, Strehl S, Nebral K, Harbott J, Teigler-Schlegel A, Zimmerman M, Dastuge N, Baruchel A, Soulier J, Auclerc MF, Attarbaschi A, Mann G, Stark B, Cazzaniga G, Chilton L, Vandenberghe P, Forestier E, Haltrich I, Raimondi SC, Parihar M, Bourquin JP, Tchinda J, Haferlach C, Vora A, Hunger SP, Heerema NA, Haas OA. An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome. Leukemia 2013, 1-7.
  • Al-Shehhi H, Konn ZJ, Schwab CJ, Erhorn A, Barber KE, Wright SL, Gabriel AS, Harrison CJ, Moorman AV. Abnormalities of the der(12)t(12;21) in ETV6-RUNX1 acute lymphoblastic leukemia. Genes, Chromosomes & Cancer 2013, 52(2), 202-213.
  • Attarbaschi A, Morak M, Cario G, Cazzaniga G, Ensor HM, te Kronnie T, Bradtke J, Mann G, Vendramini E, Palmi C, Schwab C, Russell LJ, Schrappe M, Conter V, Mitchell CD, Strehl S, Zimmermann M, Potschger U, Harrison CJ, Stanulla M, Panzer-Grumayer R, Haas OA, Moorman AV, Assoc Italiana Ematologia Oncologi, Natl Canc Res Inst NCRI-Childrens. Treatment outcome of CRLF2-rearranged childhood acute lymphoblastic leukaemia: a comparative analysis of the AIEOP-BFM and UK NCRI-CCLG study groups. British Journal of Haematology 2012, 158(6), 772-777.
  • Buitenkamp TD, Pieters R, Gallimore NE, van der Veer A, Meijerink JPP, Beverloo HB, Zimmermann M, de Haas V, Richards SM, Vora AJ, Mitchell CD, Russell LJ, Schwab C, Harrison CJ, Moorman AV, van den Heuvel-Eibrink MM, den Boer ML, Zwaan CM. Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations. Leukemia 2012, 26(10), 2204-2211.
  • Moorman AV, Schwab C, Ensor HM, Russell LJ, Morrison H, Jones L, Masic D, Patel B, Rowe JM, Tallman M, Goldstone AH, Fielding AK, Harrison CJ. IGH@ Translocations, CRLF2 Deregulation and Microdeletions in Adolescents and Adults with Acute Lymphoblastic Leukemia. Journal of Clinical Oncology 2012, 30(25), 3100-3108.
  • Rand V, Parker H, Russell LJ, Schwab C, Ensor H, Irving J, Jones L, Masic D, Minto L, Morrison H, Ryan S, Robinson H, Sinclair P, Moorman A, Strefford J, Harrison CJ. Genomic characterization implicates iAMP21 as a likely primary genetic event in childhood B-cell precursor acute lymphoblastic leukemia. Blood 2011, 117(25), 6848-6855.
  • Ensor HM, Schwab C, Russell LJ, Richards SM, Morrison H, Masic D, Jones L, Kinsey SE, Vora AJ, Mitchell CD, Harrison CJ, Moorman AV. Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial. Blood 2011, 117(7), 2129-2136.
  • Moorman AV, Ensor HM, Richards SM, Chilton L, Schwab C, Kinsey SE, Vora A, Mitchell CD, Harrison CJ. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncology 2010, 11(5), 429-438.
  • Van Vlierberghe P, Palomero T, Khiabanian H, Van der Meulen J, Castillo M, Van Roy N, De Moerloose B, Philippe J, Gonzalez-Garcia S, Toribio ML, Taghon T, Zuurbier L, Cauwelier B, Harrison CJ, Schwab C, Pisecker M, Strehl S, Langerak AW, Gecz J, Sonneveld E, Pieters R, Paietta E, Rowe JM, Wiernik PH, Benoit Y, Soulier J, Poppe B, Yao XP, Cordon-Cardo C, Meijerink J, Rabadan R, Speleman F, Ferrando A. PHF6 mutations in T-cell acute lymphoblastic leukemia. Nature Genetics 2010, 42(4), 338-342.
  • Schwab CJ, Jones LR, Morrison H, Ryan SL, Yigittop H, Schouten JP, Harrison CJ. Evaluation of Multiplex Ligation-Dependent Probe Amplification as a Method for the Detection of Copy Number Abnormalities in B-Cell Precursor Acute Lymphoblastic Leukemia. Genes, Chromosomes & Cancer 2010, 49(12), 1104-1113.
  • Russell LJ, Capasso M, Vater I, Akasaka T, Bernard OA, Calasanz MJ, Chandrasekaran T, Chapiro E, Gesk S, Griffiths M, Guttery DS, Haferlach C, Harder L, Heidenreich O, Irving JAE, Kearney L, Nguyen-Khac F, Machado L, Minto L, Majid A, Moorman AV, Morrison H, Rand V, Strefford JC, Schwab CJ, Tonnies H, Dyer MJ, Siebert R, Harrison CJ. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood 2009, 114(13), 2688-2698.

• Letters

  • Schwab C, Roberts K, Boer JM, Gohring G, Steinemann D, Vora A, Macartney C, Hough R, Thorn Z, Dillon R, Escherich G, Cazzaniga G, Schlegelberger B, Loh M, den Boer ML, Moorman AV, Harrison CJ. SSBP2-CSF1R is a recurrent fusion in B-lineage acute lymphoblastic leukemia with diverse genetic presentation and variable outcome. Blood 2021, 137(13), 1835-1838.
  • Milani G, Matthijssens F, Van Loocke W, Durinck K, Roels J, Peirs S, Thenoz M, Pieters T, Reunes L, Lintermans B, Vandamme N, Lammens T, Van Roy N, Van Nieuwerburgh F, Deforce D, Schwab C, Raimondi S, Dalla Pozza L, Carroll AJ, De Moerloose B, Benoit Y, Goossens S, Berx G, Harrison CJ, Basso G, Cave H, Sutton R, Asnafi V, Meijerink J, Mullighan C, Loh M, Van Vlierberghe P. Genetic characterization and therapeutic targeting of MYC-rearranged T cell acute lymphoblastic leukaemia. British Journal of Haematology 2019, 185(1), 169-174.
  • Chagaluka G, Carey P, Banda K, Schwab C, Chilton L, Schwalbe E, Skinner R, Israels T, Moorman A, Molyneux E, Bailey S. Treating childhood acute lymphoblastic leukemia in Malawi. Haematologica 2013, 98(1), e1-e3.
  • Buitenkamp TD, Pieters R, Zimmermann M, de Haas V, Richards SM, Vora AJ, Mitchell CD, Schwab C, Harrison CJ, Moorman AV, van den Heuvel-Eibrink MM, Zwaan CM. BTG1 deletions do not predict outcome in Down syndrome acute lymphoblastic leukemia. Leukemia 2013, 27(1), 251-252.
  • Eyre T, Schwab CJ, Kinstrie R, McGuire AK, Strefford J, Peniket A, Mead A, Littlewood T, Holyoake TL, Copland M, Moorman AV, Harrison CJ, Vyas P. Episomal amplification of NUP214-ABL1 fusion gene in B-cell acute lymphoblastic leukemia. Blood 2012, 120(22), 4441-4443.

• Review

  • Harrison CJ, Schwab C. Constitutional abnormalities of chromosome 21 predispose to iAMP21-acute lymphoblastic leukaemia. European Journal of Medical Genetics 2016, 59(3), 162-165.